SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense community polarization, with persistent criticism regarding its long-term price performance and leadership transparency contrasting against a dedicated base of "diamond-handed" investors who view current price levels as a strategic accumulation opportunity. While detractors highlight comparisons to other trending tokens and label the project a scam due to the lack of immediate price action, supporters continue to anchor their thesis on institutional developments like the Coinbase 50 inclusion and the belief that the project's utility and regulatory compliance will drive value in the coming years.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending as investors capitalize on surging gold prices and heightened market volatility, with the community actively debating whether the current price action signals a sustainable long-term breakout or an overextended blow-off top. The conversation is dominated by contrasting views on whether to continue riding the momentum in mining ETFs or prepare for a significant pullback as broader macro concerns like deficit spending and central bank policies remain central to the bullish sentiment.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is capturing investor attention as record-breaking holiday travel demand clashes with operational pressures, including government-linked disruptions and ongoing weather-related flight delays. Traders are actively debating the sustainability of current price levels, while the stock continues to see heavy call option activity and institutional interest focused on the carrier's premium positioning in a K-shaped economy.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hyperliquid ($HYPE) is capturing significant attention as traders debate its long-term utility versus competitors like Aster and Avantis, while community discussions remain split between those bullish on its deflationary tokenomics and others wary of upcoming token unlocks. The conversation is heavily focused on HYPEs role as a dominant decentralized perpetual exchange, with investors closely watching its institutional volume growth and the potential for a broader market rotation into perp-DEX platforms.

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Inventiva - ADR

Inventiva is attracting investor attention following the initiation of coverage by several analysts with buy ratings, fueling discussions about the potential of its lead asset, lanifibranor, in the MASH market. Community members are actively debating the company's valuation gap compared to sector peers and its long-term prospects as a potential acquisition target for larger pharmaceutical firms.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Toronto, Canada.

Bank of Montreal - MicroSectors Gold Miners 3X Leveraged ETN

GDXU is experiencing heightened volatility and intense community discussion following a significant pullback from recent highs, driven by shifting macroeconomic narratives and rapid price fluctuations in gold. While some traders view the current levels as a generational buying opportunity due to long-term safe-haven tailwinds, others are cautious of the 3x leverage risk, emphasizing that price discovery remains erratic as investors debate the sustainability of the current metals bull trend.

Golar LNG Ltd. owns and operates liquefied natural gas carriers, floating storage, and regasification unit. It operates through the following segments: Vessel Operations, FLNG, and Power. The Vessel Operations segment operates and charter out vessels on fixed terms to customers. The FLNG segment provides integrated upstream and midstream solution for the development of gas reserves to LNG. The Power segment integrated LNG based downstream solutions, through the ownership and operation of FSRUs and associated terminal and power generation infrastructure. The company was founded on May 10, 2001 and is headquartered in Hamilton, Bermuda.

Golar Lng

Golar LNG is trending as investors bet on the company's critical role in the global energy supply chain, specifically through its floating liquefaction infrastructure amid ongoing geopolitical tensions and tight supply constraints. Market participants are actively discussing the stock's potential to capitalize on long-term project backlogs and the broader structural shift toward mobile, reliable energy export solutions.

Cenovus Energy, Inc. is a Canadian-based integrated energy company, which engages in the provision of gas and oil. It operates through the following segments: Upstream, Downstream, and Corporate and Eliminations. The Upstream segment refers to operations of oil sands, conventional, and offshore. The Downstream segment operates the Canadian and U.S. refining. The Corporate and Eliminations segment includes the corporates costs for general and administrative. The company was founded in 1881 and is headquartered in Calgary, Canada.

Cenovus Energy Inc

Cenovus Energy is trending as investors weigh strong production growth and operational efficiency against geopolitical uncertainties that are tightening global oil supply. The community is actively debating the company's valuation, recent share buyback activity, and the long-term strategic benefits of expanding pipeline capacity to reach new export markets.

Wheaton Precious Metals Corp. is a precious metals streaming company with the quality portfolio of long-life, low-cost assets. Its business model offers investors commodity price leverage and exploration upside but with a much lower risk profile than a traditional mining company. It operates through the following business segments: Gold, Silver, Palladium, Cobalt, and Other. Wheaton was founded by Peter Derek Barnes on December 17, 2004 and is headquartered in Vancouver, Canada.

Wheaton Precious Metals Corp

Wheaton Precious Metals is surging amid investor enthusiasm for record-high precious metal prices and the companys recent strong earnings, which featured significant revenue growth and dividend increases. Community discourse is heavily focused on the stock's role as a high-margin, asset-light alternative to traditional miners, with active debate centered on whether to hold for long-term commodity strength or capitalize on current momentum.

Franco-Nevada Corp. engages in the management of gold-focused royalties and streams portfolio. It provides investors with gold price and exploration optionality while limiting exposure to many of the risks of operating companies. The company was founded in 1983 and is headquartered in Toronto, Canada.

Franco-Nevada Corporation

FNV is attracting buzz after its strong Q4 earnings beat, increased dividend, and optimistic 2026 guidance that notably excludes a Cobre Panama restart, leading the community to view any potential return of the mine as pure upside in the current booming gold market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold...

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.read more...

Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare

Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.read more...

<ul class="summary-bullets"><li>The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T cell therapy to treat pediatric tumors.</li><li>The program will receive around $1.1 million in funding to support its early-stage development.</li><li>The agreement provides for a double-digit share of future commercial revenues.</li></ul>Shares of MiNK Therapeutics (INKT) gave up most of their early gains to trade 32% higher on Tuesday after the company announced a collaboration with the C-Further, an oncology consortium, to develop a cell therapy targeting pediatric cancers.The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy to treat pediatric tumors. Preferentially Expressed Antigen in Melanoma, or PRAME, is a tumor antigen found in several cancers.MiNK’s iNKT platform aims to address key limitations of traditional cell therapies, which require patient-specific manufacturing and long preparation times.&nbsp;The therapy is derived from healthy donors and can be produced in advance, stored, and delivered when needed without complex matching or intensive pre-treatment. This approach could allow faster treatment and broader access, especially for children with aggressive cancers, the company said.&nbsp;<h2 class="st-heading-2">Program To Receive $1.1 Million In Funding</h2>By combining PRAME-targeting with MiNK’s iNKT cell platform, the therapy aims to precisely attack tumors while also activating broader immune responses.The program will receive around $1.1 million in funding to support its early-stage development, and the agreement also provides for a double-digit share of future commercial revenues, the company added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/Breakoutstockmoves/message/647092507">INKT</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/INKT_jpg_8148d6ae77.webp" alt="INKT.jpg">One user saw support at $13.5.<stembedurl>https://stocktwits.com/cjwaters14/message/647135253</stembedurl>Another user said the $1 million funding was a "small teaser" ahead of a potential buyout.<stembedurl>https://stocktwits.com/Breakoutstockmoves/message/647092507</stembedurl>Year-to-date, the stock gained 24%.For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of a trending stock chart.

Why Did INKT Stock Jump 30% Today?

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

Equity

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...

Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold"

Wall Street Zen raised shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut shares of MiNK Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INKT News

INKTMiNK Therapeutics Inc